Differenciation of Stromal-vascular Fraction CellsECTADIFNCT07567287
A Study Using Human Abdominal Adipose Tissue Biopsies to Characterize the Role of Endocannabinoids in Adipocyte Differentiation
A study testing Collection of adipose tissue samples in people with Differenciation of Stromal-vascular Fraction Cells, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
Trial summary
Abdominal obesity and type 2 diabetes are associated with hyperactivation of the endocannabinoid system. Several animal and human studies indicate that circulating endocannabinoid levels correlate with body fat mass. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Differenciation of Stromal-vascular Fraction Cells
- What is being tested?
- Collection of adipose tissue samples
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteFrance
- Study dates
- 3 Sep 2026to Sep 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Control group :
- Men or postmenopausal women aged 18 to 80
- Individuals who have provided their free and informed written consent
- Individuals scheduled to undergo abdominal surgery
- Non-diabetic obese individuals :
- Men or postmenopausal women aged 18 to 80
Show all 12Show fewer
- BMI > 30 - Individuals who have provided written, free, and informed consent
- Scheduled to undergo abdominal surgery
- Obese individuals with diabetes :
- Men or postmenopausal women aged 18 to 80 with type 2 diabetes not treated with insulin or a GLP-1 agonist
- BMI > 30
- Individuals who have provided written, free, and informed consent and are scheduled to undergo abdominal surgery
Who cannot join
- Control group :
- Individuals not enrolled in or eligible for a social security program
- Individuals subject to legal guardianship (curatorship, guardianship)
- Individuals subject to judicial protective measures
- Pregnant women, women in labor, or breastfeeding women
- Adults who are legally incapacitated or unable to give consent
Show all 43Show fewer
- Minors
- BMI > 30
- Diabetes
- Chronic inflammatory disease
- Cancer undergoing chemotherapy or having undergone chemotherapy within the past year
- Gastrointestinal cancer with recent weight loss and/or malnutrition
- Known metastatic cancers
- Cancers undergoing long-term hormonal therapy
- Any positive result for screening for human immunodeficiency virus (HIV) infection, hepatitis B surface antigen testing, or testing for antibodies against the hepatitis C virus (HCV) with a positive HCV RNA test.
- Non-diabetic obese individuals :
- Individuals not enrolled in or eligible for a social security program
- Individuals subject to legal guardianship (curatorship, guardianship)
- Individuals subject to judicial protective measures
- Pregnant women, women in labor, or breastfeeding women
- Adults who are legally incapacitated or unable to give consent
- Minors
- Diabetes
- Chronic inflammatory disease
- Cancer undergoing chemotherapy or having undergone chemotherapy within the past year
- Gastrointestinal cancer with recent weight loss and/or malnutrition
- Known metastatic cancers
- Cancers undergoing long-term hormonal therapy,
- Any positive result for screening for human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or antibodies to hepatitis C virus (HCV) with a positive HCV RNA test.
- Obese individuals with diabetes
- Individuals not enrolled in or not eligible for a social security program
- Individuals subject to legal guardianship (curatorship, guardianship)
- Individuals subject to judicial protective measures
- Pregnant women, women in labor, or breastfeeding women
- Adults who are legally incapacitated or unable to give consent
- Minors
- Diabetes
- Chronic inflammatory disease
- Cancer undergoing chemotherapy or having undergone chemotherapy within the past year
- Gastrointestinal cancer with recent weight loss and/or malnutrition
- Known metastatic cancers
- Cancers undergoing long-term hormonal therapy,
- Any positive result for screening for human immunodeficiency virus (HIV) infection, hepatitis B surface antigen, or antibodies against hepatitis C virus (HCV) with a positive HCV RNA test.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Chu Dijon Bourgogne
Dijon
Bruno VERGES, 03.80.29.38.54 ext. +33, bruno.verges@chu-dijon.fr
About this study
Official title: A Basic Study Using Human Abdominal Adipose Tissue Biopsies to Characterize the Role of Endocannabinoids in Adipocyte Differentiation
Abdominal obesity and type 2 diabetes are associated with hyperactivation of the endocannabinoid system. Several animal and human studies indicate that circulating endocannabinoid levels correlate with body fat mass. Thus, adipose tissue, which possesses the enzymatic machinery of the endocannabinoid system, may be the primary producer of plasma endocannabinoids.
Today, it is well established that stimulation of the endocannabinoid system, through the activation of cannabinoid receptor 1 (CB1R) located in the brain, leads to increased food intake and weight gain. Furthermore, peripheral CB1R present in adipose tissue are also directly involved in energy storage processes. Indeed, activation of the endocannabinoid system in adipose tissue is associated with stimulation of pathways leading to the uptake of carbohydrates and fatty acids, as well as their storage in the form of triglycerides.
Read more
Adipose tissue consists primarily of mature adipocytes, and activation of the endocannabinoid system appears to play a key role in increasing fat mass by promoting the hypertrophy of these adipocytes through the stimulation of lipogenesis. However, the vascular stromal fraction also contains stem cells capable of generating new adipocytes, and an autocrine action of endocannabinoids on progenitor cells could also contribute to its expansion by promoting hyperplasia.
That is why, in this project, the investigators aim to study the impact of endocannabinoids on the differentiation of stem cells from the stromal-vascular fraction into adipocytes. In particular, the investigators will seek to compare the impact of endocannabinoids on the differentiation capacity of stem cells derived from adipose tissue collected from patients with obesity, with or without diabetes, compared to controls.
These data, combined with those obtained in parallel in mice, could help determine whether adipose tissue (visceral and/or subcutaneous) is a priority target for the development of CB1R-blocking molecules (such as rimonabant) with exclusively peripheral action (which do not cross the blood-brain barrier to avoid psychiatric side effects) for the treatment of metabolic obesity and type 2 diabetes.
- Being tested
- Collection of adipose tissue samples
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collection of adipose tissue samplesDiagnostic test
Collection of small-volume adipose tissue samples (a few cubic centimeters) during a previously scheduled abdominal surgery.
| Study group | Role | What they receive |
|---|---|---|
| Control group | Other | Not described Receives: Diagnostic Test: Collection of adipose tissue samples |
| Non-diabetic obese individuals | Other | Not described Receives: Diagnostic Test: Collection of adipose tissue samples |
| Obese individuals with diabetes | Other | Not described Receives: Diagnostic Test: Collection of adipose tissue samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
Monitoring the differentiation of stem cells from the stromal-vascular fraction into adipocytes
- Stem cell population in the stromal-vascular fraction prior to culture
- Monitoring of stem cell differentiation into adipocytes in the presence of a CB1 receptor agonist, antagonist, or solvent (Oil Red O staining, mRNA markers, flow cytometry)
- Kinetics of endocannabinoid release by cells during differentiation, assessed by RT-PCR of mRNAs. Quantification will be performed by liquid chromatography coupled with mass spectrometry (LC-MS).
Measured: At baseline, biopsies of visceral and subcutaneous adipose tissue will be performed in the operating room during patients' visceral surgery. The samples will be promptly transferred to the INSERM laboratory for stem cell culture to assess adipocyte diffe
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 May 2026
- Study start3 Sep 2026
- Primary completionSep 2028 (estimated)
- Study completionSep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Differenciation of Stromal-vascular Fraction CellsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire Dijon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07567287
- Sponsor's protocol ID
- VERGES 2025
- Acronym
- ECTADIF
- Status last verified
- Sep 2026
- First submitted
- 24 Apr 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Basic Study Using Human Abdominal Adipose Tissue Biopsies to Characterize the Role of Endocannabinoids in Adipocyte Differentiation
- ClinicalTrials.gov ID
- NCT07567287
- Acronym / sponsor ID
- ECTADIF / VERGES 2025
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire DijonUniversity, hospital or other
- Study start
- 3 Sep 2026 (actual)
- Primary completion
- Sep 2028 (estimated)
- Study completion
- Sep 2028 (estimated)
- First posted
- 5 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Abdominal obesity and type 2 diabetes are associated with hyperactivation of the endocannabinoid system. Several animal and human studies indicate that circulating endocannabinoid levels correlate with body fat mass. Thus, adipose tissue, which possesses the enzymatic machinery of the endocannabinoid system, may be the primary producer of plasma endocannabinoids.
Today, it is well established that stimulation of the endocannabinoid system, through the activation of cannabinoid receptor 1 (CB1R) located in the brain, leads to increased food intake and weight gain. Furthermore, peripheral CB1R present in adipose tissue are also directly involved in energy storage processes. Indeed, activation of the endocannabinoid system in adipose tissue is associated with stimulation of pathways leading to the uptake of carbohydrates and fatty acids, as well as their storage in the form of triglycerides.
Adipose tissue consists primarily of mature adipocytes, and activation of the endocannabinoid system appears to play a key role in increasing fat mass by promoting the hypertrophy of these adipocytes through the stimulation of lipogenesis. However, the vascular stromal fraction also contains stem cells capable of generating new adipocytes, and an autocrine action of endocannabinoids on progenitor cells could also contribute to its expansion by promoting hyperplasia.
That is why, in this project, the investigators aim to study the impact of endocannabinoids on the differentiation of stem cells from the stromal-vascular fraction into adipocytes. In particular, the investigators will seek to compare the impact of endocannabinoids on the differentiation capacity of stem cells derived from adipose tissue collected from patients with obesity, with or without diabetes, compared to controls.
These data, combined with those obtained in parallel in mice, could help determine whether adipose tissue (visceral and/or subcutaneous) is a priority target for the development of CB1R-blocking molecules (such as rimonabant) with exclusively peripheral action (which do not cross the blood-brain barrier to avoid psychiatric side effects) for the treatment of metabolic obesity and type 2 diabetes.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control group | Other | Diagnostic Test: Collection of adipose tissue samples |
| Non-diabetic obese individuals | Other | Diagnostic Test: Collection of adipose tissue samples |
| Obese individuals with diabetes | Other | Diagnostic Test: Collection of adipose tissue samples |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Control group :
- Non-diabetic obese individuals :
- Obese individuals with diabetes :
Key exclusion criteria (43 listed)
- Control group :
- Non-diabetic obese individuals :
- Obese individuals with diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collection of adipose tissue samplesCollection of small-volume adipose tissue samples (a few cubic centimeters) during a previously scheduled abdominal surgery. | Diagnostic test | Control group, Non-diabetic obese individuals, Obese individuals with diabetes |
Primary outcome
Monitoring the differentiation of stem cells from the stromal-vascular fraction into adipocytes
Time frame: At baseline, biopsies of visceral and subcutaneous adipose tissue will be performed in the operating room during patients' visceral surgery. The samples will be promptly transferred to the INSERM laboratory for stem cell culture to assess adipocyte diffe
* Stem cell population in the stromal-vascular fraction prior to culture * Monitoring of stem cell differentiation into adipocytes in the presence of a CB1 receptor agonist, antagonist, or solvent (Oil Red O staining, mRNA markers, flow cytometry) * Kinetics of endocannabinoid release by cells during differentiation, assessed by RT-PCR of mRNAs. Quantification will be performed by liquid chromatography coupled with mass spectrometry (LC-MS).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Collection of adipose tissue samples in people with Differenciation of Stromal-vascular Fraction Cells, run by Centre Hospitalier Universitaire Dijon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 43 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bruno VERGES (03.80.29.38.54 ext. +33, bruno.verges@chu-dijon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Monitoring the differentiation of stem cells from the stromal-vascular fraction into adipocytes (time frame: At baseline, biopsies of visceral and subcutaneous adipose tissue will be performed in the operating room during patients' visceral surgery. The samples will be promptly transferred to the INSERM laboratory for stem cell culture to assess adipocyte diffe). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026; AzTrials last refreshed its copy on 29 Oct 2026.